What the Study Found (In Plain English)
Published in International journal of obesity (2005) (2012), this randomized controlled trial evaluating 564 human participants investigated: Having demonstrated short-term weight loss with liraglutide in this group of obese adults, we now evaluate safety/tolerability (primary outcome) and long-term efficacy for sustaining weight loss (secondary outcome) over 2 years. Key clinical takeaway: Liraglutide is well tolerated, sustains weight loss over 2 years and improves cardiovascular risk factors.
Dr. Lin (AI Evidence Lead): Statistical Endpoints & Numbers
Primary Endpoint & Quantitative Summary (International journal of obesity (2005), 2012-06-15; N = 564; Rigor 93/100): Liraglutide is well tolerated, sustains weight loss over 2 years and improves cardiovascular risk factors.
Study Limitations & Caveats Before You Act
Clinical trials evaluate specific inclusion/exclusion cohorts under protocol-controlled conditions (Randomized Controlled Trial). Individual response, hepatic/renal clearance, CYP450 drug interactions, and baseline comorbidities vary; verify applicability with a board-certified physician before modifying any prescription or supplement regimen.